Editor's Audio Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the January 15, 2014 issue
To determine the effects of secretory phospholipase A2 inhibition with varespladib on cardiovascular outcomes, Nicholls and coauthors randomized 5145 patients within 96 hours of presentation of an acute coronary syndrome to either varspladib (n = 2572) or placebo (n = 2573) for 16 weeks.
Primrose and coauthors conducted a randomized clinical trial among 1202 patients at 39 hospitals in England to assess the effectiveness of blood measurement of carcinoembryonic antigen (CEA) and computed tomography (CT) as follow-up to detect recurrent colorectal cancer treatable with curative intent.
In a multicenter, prospective, observational trial at 6 US sites, Criqui and colleagues study a diverse cohort of 3398 men and women, aged 45 to 84 years, to determine the independent associations of coronary artery calcium (CAC) volume and CAC density with incident cardiovascular disease events. In a related Editorial, Greenland discusses more evidence for CAC as a measure of cardiovascular risk.
Steele and coauthors assess the association between chronic mild hyperglycemia and complication prevalence and severity among 271 participants in the United Kingdom.
After analyzing 80 articles, Morris and coauthors report that recent studies demonstrat a lesser role for aggressive antibiotic or surgical intervention for recurrent or chronic diverticulitis.